Kineta Two, LLC

Illumigen Biosciences, Inc.

Ib Security Holders LLC

Charles Lee Magness

Shawn P Iadonato

Christina A Scherer

Maralee McVean

Mark Branum

Gary Rosenberg

Thierry Guillaudeux

Amy Olson

Tory Hagen

P Campion Fellin

Dake Sun

Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.

Mutations in OAS1 genes

A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.

Detection of mutations in a gene associated with resistance to viral infection, OAS1

The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.

Oligoadenylate synthetase (OAS)

Pharmaceutical compositions for the treatment of virus infection

A technique is disclosed for classifying a population of subjects into various sub-populations for a selected biological condition. Patients are categorized in accordance with numeric scores for a affected status for the selected biological condition and a risk status for the selected biological condition. The numeric scores for an overall population are determined in advance for the selected biological condition. Medical test results, including genetic tests, and risk factors are numerically scored and may further be weighted in accordance with their relevance in determining affected status and risk. Medical test results and medical histories for individual subjects within the population may then automatically be scored in accordance with the predefined characteristics. The numerical scores for affected status and risk status may be stored in a data structure, such as a database. The numeric scores are extracted from the data structure and used to classify individuals in the population into one of a group of selected sub-populations comprising at-risk affected (ARA) and at-risk unaffected (ARU). Additional sub-populations, such as unknown risk, unaffected (URU) may also be used.

System and method for selectively classifying a population

Oligoadenylate Synthetase (OAS)

This invention provides methods for identifying mutations and methylation patterns in diploid DNA sequence signal data. In particular, the invention provides methods for (1) obtaining two parental allele sequences from diploid DNA sequence signal data, (2) identifying the mutation and haplotype patterns in the two parental allele sequences, (3) assigning likelihood scores for the mutations thus identified, and (4) identifying patterns of methylation.

Method and apparatus for pattern identification in diploid DNA sequence data

Growing community of inventors

Seattle, WA, United States of America

Charles Lee Magness